The Serum Institute of India has been granted approval by the Drug Controller General of India to manufacture the Sputnik V coronavirus jab for examination, test, and analysis, just days after applying to the DCGI.
On Thursday, the business filed an application with the DCGI in this respect.
The Pune-based SII worked with Russia’s Gamaleya Research Institute of Epidemiology and Microbiology to build Sputnik V at its licenced Hadapsar facility, according to the report.
According to initial reports, the Russian vaccine will be given in two doses separated by 21 days. The two doses of Sputnik V have a 91 per cent efficacy rate, whereas the single dose has a 79.4 per cent efficacy rate, according to Gamaleya. According to Gamaleya, the vaccination has been approved in over 65 nations thus far.
The Russian vaccine has been approved for use in more than 65 nations, but the EU and US health authorities have yet to authorise it. Sputnik V has better efficacy than the two vaccines now being used in India: Oxford-Covishield, AstraZeneca’s made by the SII, and Bharat Biotech’s Covaxin, both of which have an efficacy of 91.6 per cent.